Zeneca Agrees to Purchase 50% Interest in Salick Health Care, Inc.

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

LONDON, UK--As Oncology News International (ONI) went to press, we received news that Zeneca Group PLC has agreed to buy a 50% interest in Salick Health Care, Inc (Los Angeles). The agreement is subject to shareholder approval and US regulatory review, the company said.

LONDON, UK--As Oncology News International (ONI) went to press,we received news that Zeneca Group PLC has agreed to buy a 50%interest in Salick Health Care, Inc (Los Angeles). The agreementis subject to shareholder approval and US regulatory review, thecompany said.

Salick Health Care operates 10 comprehensive cancer care centers,offers specialized inpatient and outpatient services through itssubsidiaries, and operates SalickNet, a managed care subsidiary.

A full report on the agreement will appear in the February, 1995,issue of Oncology News International.

Articles in this issue
MDs Fear Managed Care Equals Lower-Quality Care
Dallas Medical Center Launches Umbilical Stem Cell Project
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
European Trials Show Dose-Related Efficacy of Docetaxel In Metastatic Breast Cancer, Value of Steroid Pretreatment
Ethyol Approved for Use in the UK
Success of Breast Conserving Surgery Is Not Diminished in Community Setting
Assessment Tools Are Essential to Improve Management of Pain
Undertreating Pain Costs Money in the Long Run, Physician Warns
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
EORTC Endometrial Ca Trial Challenges Findings From GOG
Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small
Antibiotic Regimen Leads to Lymphoma Regression
Look for Incremental Insurance Reform Steps With New Congress
Court Upholds Patents on AZT
Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer
Recent Videos
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Related Content
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Forming International Collaborative Efforts to Assess Metformin Use in LFS

Russ Conroy
October 24th 2024
Article

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

ONCOLOGY Staff
October 24th 2024
Article

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC

Roman Fabbricatore
October 23rd 2024
Article

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Expert Commentary on the Product Profile of Lazertinib in NSCLC

Expert Commentary on the Product Profile of Lazertinib in NSCLC

Jenan Dailey, PharmD, BCAP
October 23rd 2024
Article

Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.